Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06088199 · ClinicalTrials.gov registry record · Phase 3
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
A Phase 3 study of Plaque Psoriasis, sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 51
- Enrollment target
- 20
- Study locations
NCT06088199 is a Phase 3 study of Plaque Psoriasis that is active but no longer recruiting, run by Amgen. The registered enrollment target is 51 participants, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT06088199, a Phase 3 study of Plaque Psoriasis, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 51 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
Conditions Studied
Interventions
- DRUG Apremilast
Study Locations (20)
California
- Avance Clinical Trials - Laguna Niguel
- University of California Irvine - Orange
- MedDerm Associates - San Diego
- Clinical Science Institute - Santa Monica
- California Dermatology Institute - Thousand Oaks
Florida
- Pediatric Skin Research LLC - Coral Gables
- Ciocca Dermatology - Miami
- University of South Florida - Tampa
Arizona
- Affiliated Dermatology - Scottsdale
- Clear Dermatology - Scottsdale
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
- Southern Indiana Clinical Trials - New Albany
Michigan
- Great Lakes Research Group Inc- Sheffield - Bay City
- Henry Ford Medical Center - New Center One - Detroit
Alabama
- University of Alabama at Birmingham - Birmingham
Arkansas
- Johnson Dermatology Clinic - Fort Smith
Illinois
- Endeavor Health Clinical Trials Center - Skokie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2023-10-24 |
| Est. Completion | 2026-08-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06088199
The ClinicalTrials.gov registry entry for NCT06088199 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (88% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Apremilast is the first listed.
NCT06088199 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06088199 about?
NCT06088199 is a clinical study titled "A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis". The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
What is the current status of trial NCT06088199?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 51 participants. The study started on 2023-10-24. Estimated completion is 2026-08-06.
What conditions does trial NCT06088199 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT06088199?
The interventions under investigation include: Apremilast (DRUG).
Who is sponsoring clinical trial NCT06088199?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06088199 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.